Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-Cell Vaccination in Probable Multiple Sclerosis
NCT00228228Phase 3Unknown
- Sponsor
- Sheba Medical Center
- Start
- May 2002
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of autologous T cell lines reactive to nine myelin peptides in multiple sclerosis (MS), sponsored by Sheba Medical Center. Status: unknown.
02
Drugs
autologous T cell lines reactive to nine myelin peptides
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT00228228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00228228.